

Meningitis

Community-Acquired:

No recent neurosurgery or invasive neurological procedure (e.g. intrathecal pump insertion). Absence of encephalitis.

Post-Neurosurgical:

<u>Recent neurosurgery or invasive neurological procedure</u> -<u>infection attributable to device implantation in neural tissue</u> <u>(e.g. spine stimulator). Absence of encephalitis.</u>

Encephalitis:

Patient has symptoms of seizures, altered mental status, and focal neurologic signs. Absence of neck stiffness or jolt accentuation.



Community-Acquired Meningitis

Treatment duration is based on causative organism (see below). Aseptic meningitis is often caused by viruses. For other organisms, please contact Infectious Diseases or Medical Microbiology. Tailor treatment once cultures are available, if culture is negative by day 3, consider discontinuing antibiotics.

Empiric therapy

Drug	Dose	Route	Duration		
Ceftriaxone	2 g q12h	IV	2-3 days then reassess		
If ceftriaxone allergy: Meropenem 2 g IV q8h x 2-3 days then reassess					
→If elderly/immune-suppressed <u>ADD</u> to ceftriaxone ONE of:					

Ampicillin	2 g q4h	IV	2-3 days then reassess
TMP-SMX	5 mg/kg q6h	IV	2-3 days then reassess

→If suspected *S. pneumoniae* resistance, <u>ADD</u> to ceftriaxone:

Vancomycin	Load 30 mg/kg, then	IV	2-3 days then reassess
	20 mg/kg q8-12h		

Directed therapy (if susceptible)

S. pneumoniae	Penicillin	4 MU q4h	IV	10-14 days
H. influenzae	Ampicillin	2 g q4h	IV	10 days
N. meningitidis	Penicillin	4 MU q4h	IV	5 days
L. monocytogenes	Ampicillin	2 g q4h	IV	21 days

<section-header><section-header><section-header><section-header><section-header><section-header><text><text>



TMP-SMX = trimethoprim-sulfamethoxazole (cotrimoxazole)



Post-Neurosurgical Meningitis

Meningitis developing after neurosurgery or CNS manipulation is commonly caused by organisms introduced at the time of surgery, which may include coagulase-negative staphylococci and nonfermenting gram negative rods such as *P. aeruginosa*. Empiric therapy should cover broadly, but be narrowed as soon as the causative pathogen is identified.

Treatment duration for proven post-surgical meningitis is dependent on the pathogen, presence of prosthetic hardware, and other factors. Please contact Infectious Diseases to assist in determining the duration of therapy.

Drug	Dose	Route	Duration			
Meropenem	2 g q8h	IV	10 days then reassess			
OR						
Ceftazidime	2 g q8h	IV	10 days then reassess			
AND						
Vancomycin	Load 30 mg/kg, then 20 mg/kg q8-12h	IV	10 days then reassess			

Meningitis

Community Acquired: tient has not had recent neurosurgery or other invision of neurof houses for a linear thread areas

Post NeuroSurgical a sector has had a receil measure of alexandruk of the tar above alexandruk of Alexandruk of the alexandruk of the tar above alexandruk of Alexandruk of the alexandruk of the Encephalitis





Encephalitis

Encephalitis is distinguished from meningitis by seizures, changes in behaviour, confusion and disorientation, without prominent meningitic signs. It is most commonly caused by viruses (e.g. herpes simplex virus, arthropod-borne [West Nile virus]), although most causes are never identified.

Drug	Dose	Route	Duration
Acyclovir	10 mg/kg q8h	IV	14 days then reassess

Step-down option

Antiviral therapy should be stopped if herpes virus is determined to not be responsible for infection. Other viral infections require supportive care alone, since anti-virals have not been shown to be beneficial. If a specific virus is identified, contact Infectious Diseases for further guidance. Once patient is clinically improving and able to take or absorb oral medications, consider step-down:

Drug	Dose	Route	Duration
Valacyclovir	1000 mg TID	РО	Up to 14-21 days of total therapy







Pharyngitis - Acute

Viral etiology is responsible for majority of cases in adults (80-90%) and do not require antimicrobial therapy. Group A *Streptococcus* (GAS) is most common bacterial cause of pharyngitis. Occasionally pharyngitis is caused by Group C, G streptococci and *Arcanobacterium haemolyticum*

Acute (preferred therapy)

Drug	Dose	Route	Duration
Penicillin VK	600 mg BID or 300 mg TID	РО	10 days

Relapse or Recurrent (confirm by culture)

Drug	Dose	Route	Duration
Clindamycin	300 mg TID	РО	10 days
Amoxicillin-clavulanate	875-125 mg BID	РО	10 days

If severe penicillin allergy

Drug	Dose	Route	Duration
Cephalexin	500 mg BID	РО	10 days
Clindamycin	300 mg TID	РО	10 days
Azithromycin	500 mg daily	РО	3 days
Clarithromycin	250 mg BID	РО	10 days

Click link for Gonococcal Pharyngitis





Pharyngitis -Gonococcal

Caused by *Neisseria gonorrhoeae*. Test of cure recommended after completion of therapy.

Preferred therapy, choose ONE of:

Drug	Dose	Route	Duration	
Ceftriaxone	250 mg	IM	1 dose	
Cefixime	800 mg	РО	1 dose	
AND choose ONE of:				
Azithromycin	1 g	РО	1 dose	
Doxycycline	100 mg BID	РО	7 days	

If severe cephalosporin allergy

Drug	Dose	Route	Duration
Azithromycin	2 g	РО	1 dose





Infective Endocarditis (IE)

Native Valve (NVE):

<u>Empiric Therapy</u> <u>Staphylococcus aureus</u> Viridans group streptococci (VGS) <u>Enterococci</u> <u>HACEK organisms</u>

Prosthetic Valve (PVE):

<u>Empiric Therapy</u> <u>Staphylococcus aureus</u> <u>Viridans group streptococci (VGS)</u> <u>Group A, B,C,G streptococci</u> <u>Enterococci</u> <u>HACEK organisms</u>

General approach

- Draw blood cultures, ideally 2 to 3 sets over 1 hour.
- Tailor therapy to culture and sensitivities, once available.
- Right-sided infective endocarditis (RSIE) accounts for only 5–10% of cases; the majority involves the tricuspid valve and generally occurs among injection drug users and where intravenous lines and wires (e.g. pacemakers) are present.
- Left-sided IE (LSIE) involves the mitral or aortic valve.

Empiric therapy:

Drug	Dose	Route	Duration	
Ceftriaxone	2 g q24h	IV	Until diagnosis is confirmed	
AND				
Vancomycin	Load 30 mg/kg, then 15 mg/kg q8-12h	IV	Until diagnosis is confirmed	
Endocarditis				

Native Valve: Empiric Therapy <u>Staphylococcus aureus</u> iridans group streptococci (VGS)

Enterococci HACEK <u>organisms</u> Prosthetic Valve: Empiric Therapy Staphylococcus ourcus Viridans group streptococci (VGS) Group A, B,C,G Streptococci

Enterococci HACEK organisms



Native Valve Infective Endocarditis

Staphylococcus aureus

Mean duration of bacteremia with *S. aureus* is approximately 7 days. Cultures should be drawn daily for 3 days, then every 3 days until clear. Infectious diseases should always be consulted for cases of *S. aureus* bacteremia; **it is the responsibility of the MRP to consult ID**. Consider echocardiogram and investigation for occult sources, such as osteomyelitis.

Preferred regimens, if susceptible

Drug	Dose	Route	Duration
Cloxacillin	2 g q4h	IV	6 weeks
OR			for left-sided IE or complicated right- sided IE
Cefazolin	2 g q8h	IV	2 weeks for uncomplicated right-sided IE

If severe penicillin/cefazolin allergy, or MRSA with vancomycin MIC $\leq 2 \mu g/mL$

Vancomycin	Load 30 mg/kg, then	IV	6 weeks
	15 mg/kg q8-12h		

If MRSA with vancomycin MIC >2 μ g/mL - Consult Infectious Diseases

Uncomplicated right-sided IE: no evidence of renal failure, extrapulmonary metastatic infections, aortic or mitral valve involvement, meningitis, or infection by MRSA

Native Valve: Staminc Therapy Staminc Therapy Staminc Concerns (VGS) Entertocol: HACEK organisms Prosthetic Valve: Empiric Therapy Staminocous surves Viridam group. Streptococci (VGS) Group. A. E. G. Streptococci





Prosthetic Valve Infective Endocarditis

Staphylococcus aureus

Preferred regimens, if susceptible

Drug	Dose	Route	Duration	
Cloxacillin	2 g q4h	IV	6 weeks	
AND				
Rifampin	300 mg TID	PO	6 weeks	
AND				
Gentamicin	1 mg/kg q8h	IV	2 weeks	

If severe penicillin allergy, or MRSA with vancomycin MIC $\leq 2 \mu g/mL$

Vancomycin	Load 30 mg/kg, then 15 mg/kg q8-12h	IV	6 weeks	
AND				
Rifampin	300 mg TID	РО	6 weeks	
AND				
Gentamicin	1 mg/kg q8h	IV	2 weeks	

If MRSA with vancomycin MIC >2 μ g/mL - Consult Infectious Diseases







Viridans group streptococci (VGS) and β-hemolytic (group A,B,C,G) streptococci

VGS – Penicillin-susceptible MIC ≤0.12 µg/mL or β-hemolytic Strep

Drug	Dose	Route	Duration	
Penicillin G	3 MU q4h 4 MU q4h	IV IV	4 weeks (NVE) 6 weeks (PVE)	
	OR			
Penicillin + Gentamicin	3 MU q4h 3 mg/kg q24h	IV IV	2 weeks (NVE)	
VGS – Penicillin M	C >0.12-<0.5 µg/mL &	ceftriaxone	e MIC ≤ 1 μg/mL	
Ceftriaxone	2 g q24h	IV	4 weeks (NVE)	
Penicillin + Gentamicin	4 MU q4h 3 mg/kg q24h	IV IV	6 weeks (PVE)	
VGS – Penicillin-res	istant MIC ≥0.5 μg/mL	& Ceftriaxo	one MIC ≤1 µg/mL	
Ceftriaxone	2 g q24h	IV	4 weeks (NVE) 6 weeks (PVE)	
	ADD			
Gentamicin	3 mg/kg q24h	IV	4 weeks (NVE) 6 weeks (PVE)	
If severe penicilli	n/ceftriaxone allergy, c	or ceftriaxo	ne MIC ≥2 μg/mL	
Vancomycin Endocarditis Native Valve:	Load 30 mg/kg, then 15 mg/kg q8-12h	5 IV	4 weeks (NVE) 6 weeks (P <mark>VE</mark>)	
Native Value Subjection Subjection Subjecti				

Enterococci

Preferred regimens, if susceptible

Drug	Dose	Route	Duration		
Ampicillin	2 g q4h	IV	4 weeks For symptoms <3 mo 6 weeks For symptoms >6 mo		
*	Consult ID to consider A	DDING:*			
Ceftriaxone	2g q12h	IV	4-6 weeks		
	OR				
Gentamicin	1 mg/kg q8h	IV	4-6 weeks		
If severe penicill	If severe penicillin allergy				
Vancomycin	Load 30 mg/kg, then 15 mg/kg q8-12h	IV	6 weeks		
Consult ID to consider ADDING:					
Gentamicin	1 mg/kg q8h	IV	6 weeks		







HACEK organisms

Haemophilus spp, Aggregatibacter spp, Cardiobacterium hominis, Eikenella corrodens, Kingella spp

Tailor to culture and susceptibilities:

Drug	Dose	Route	Duration
Ceftriaxone	2 g q24h	IV	4 weeks (NVE) 6 weeks (PVE)
Ampicillin	2 g q4h	IV	4 weeks (NVE) 6 weeks (PVE)

If severe penicillin allergy

Drug	Dose	Route	Duration
Ciprofloxacin	400 mg q12h	IV	4 weeks (NVE) 6 weeks (PVE)
Ciprofloxacin	500 mg BID	РО	4 weeks (NVE) 6 weeks (PVE)







Acute Exacerbation of Chronic Bronchitis (AECB)

Antibiotic therapy is only recommended if two or more are present:

↑ sputum volume

 \uparrow sputum purulence

↑ dyspnea.

Approximately 50% of acute exacerbations of chronic bronchitis are caused by viruses.

Simple AECB (<4 exacerbations/year), choose ONE of:

• •			
Drug	Dose	Route	Duration
Amoxicillin	500-1000 mg TID	РО	5 days
Doxycycline	200 mg x 1, then 100 mg BID	РО	5 days
Cotrimoxazole	1 DS tab BID	РО	5 days
Azithromycin	500 mg daily	РО	3 days
Clarithromycin	500 mg BID or XL 1 g daily	PO	5 days

Complicated AECB (>4 exacerbations/year), choose ONE of:

Drug	Dose	Route	Duration
Amoxicillin-clavulanate	875-125 mg BID	РО	5 days
Cefuroxime	500 mg TID	РО	5 days

If severe beta-lactam allergy

Drug	Dose	Route	Duration
Moxifloxacin	400 mg daily	РО	5 days



Pneumonia

Community-Acquired

Hospital-Acquired

Aspiration



Community-Acquired Pneumonia

Calculate the CRB-65 score:

Parameter	Criteria	Add to Score
Confusion	<u>New</u> disorientation to person, place, or time	+1
R espiratory Rate	≥ 30 breaths per minute	+1
Blood Pressure	SBP < 90 mmHg or DBP < 60 mmHg	+1
Age ≥ 65 years		+1

Total Score: Click the calculated value

0	1	2	3	4
Mild	Mild	Moderate	Severe	Severe



Mild CAP – CRB-65 = 0-1

Patients with CRB-65 scores of 0 (30d mortality of 0.6%) or 1 (30d mortality of 2.7%) should be considered for outpatient oral therapy. Patients admitted to hospital do not require IV therapy, unless they are unable to take or absorb oral medication.

Preferred therapy

Drug	Dose	Route	Duration
Amoxicillin	500 mg or 1000 mg TID	РО	5 days

Penicillin/amoxicillin allergic with no severe delayed reaction to β -lactams (e.g. SJS, TENS, DRESS)

Drug	Dose	Route	Duration
Cefuroxime	500 mg TID	РО	5 days

If severe penicillin/amoxicillin & cefuroxime allergy

Drug	Dose	Route	Duration
Doxycycline	100 mg BID	РО	5 days





Moderate CAP – CRB-65 = 2

Patients with CRB-65 scores of 2 (30d mortality of 6.8%) may be discharged home or admitted to hospital. Oral therapy is preferred, but IV therapy may be appropriate with step-down to oral therapy as soon as possible. Quinolones are recommended only in exceptional circumstances and should not be prescribed routinely.

Preferred therapy, choose ONE of:

Drug	Dose	Route	Duration		
Amoxicillin-clavulanate	875 mg BID	РО	5 days		
Cefuroxime	500 mg TID	РО	5 days		
\rightarrow If unable to tolerate P	O or IV therapy re	equired			
Ceftriaxone	1 g q24h	IV	5 days		
→If atypical infection suspected, <u>ADD</u> ONE of:					
Azithromycin	500 mg daily	PO or IV	3 days		
Doxycycline	100 mg BID	РО	5 days		
Second-line (if penicillin/cefuroxime/ceftriaxone allergy)					
Moxifloxacin	400 mg daily	PO or IV	5 days		







Severe CAP – CRB-65 = 3-4

Patients with CRB-65 scores of 4 or 5 (30-day mortality of 27.8%) are considered to have severe disease. Patients could be managed on the ward or in the ICU. IV therapy should be started with dual therapy recommended for most patients.

Preferred therapy

Drug	Dose	Route	Duration		
Ceftriaxone	2 g q24h	IV	5 days		
	AND ONE	of:			
Azithromycin	500 mg q24h	PO or IV	3 days		
Doxycycline	100 mg BID	PO	5 days		
Second-line (if ceftriaxone allergy)					
Moxifloxacin	400 mg daily	PO or IV	5 days		
→ If MRSA or other Gram+ resistant organism suspected, <u>ADD</u> :					
Vancomycin	Load 25-30 mg/kg, then 15 mg/kg q8-12h	IV	7 days (min.) Up to 14 days if bacteremia		





Hospital-acquired Pneumonia (HAP)

Hospital-acquired pneumonia can be categorized into early onset vs. late onset.

- Early onset <4 days See Community-acquired Pneumonia
- Late onset >4 days Develops after 4 days of hospitalization
- Usual pathogens for HAP include Enterobacterales

Preferred therapy (late onset HAP with no risk factors)

Drug	Dose	Route	Duration
Ceftriaxone	1 g q24h	IV	7 days
Cefuroxime	500 mg TID	PO	7 days
Moxifloxacin	400 mg q24h	PO/IV	7 days

Preferred therapy (late onset HAP - <3 months broad spectrum antibiotics, lung disease, immunosuppression)

Piperacillin-tazobactam	3.375	g q6h	IV		7 days
Meropenem	500 n	ng q6h	IV		7 days
Step-down option (based on susceptibilities or as empiric therapy)					
Amoxicillin-clavulana	te	875/125 r	ng BID	РО	As above
Cefuroxime (if penicillin al	lergic)	500 mg	; TID	PO	As above

→ If MRSA or other Gram+ resistant organism suspected, ADD:

Vancom	ycin	Load 25-30 mg/kg, then 15 mg/kg q8-12h	IV	7 days (min.) Up to 14 days bacteremia
CE 1				a se a

Aspiration Pneumonia

Aspiration of gastric contents can cause a pneumonitis (inflammatory reaction) that is not infectious and does not require antibiotic therapy. Aspiration pneumonia is usually associated with radiographic infiltrates in the RLL, and clinical and systemic symptoms of pneumonia.

Preferred therapy (mild to moderate)

Drug	Dose	Route	Duration
Amoxicillin-clavulanate	875 mg BID	PO	7 days
Ceftriaxone	1 g q24h	IV	7 days

→ If risk factors for anaerobes (poor oral hygiene, periodontal disease, putrid sputum), <u>ADD</u>:

Metronidazole	500 mg q12h	PO/IV	7 days			
Preferred therapy (hospital-acquired – severe)						
Piperacillin-tazobactam	3.375 g q6h	IV	7 days			

			-
Meropenem	500 mg q6h	IV	7 days

Second-line (if allergic to preferred therapy)

Moxifloxacin	400 mg daily	PO or IV	5 days
--------------	--------------	----------	--------





Cholecystitis

Management should involve source control. Oral step-down should be considered as soon as patient tolerates oral intake. Shorter duration of therapy (3 days or 24 hours post ERCP) should be considered in the absence of cholangitis, abscess, or perforation.

Mild (no hospitalization)

No antimicrobials required

Moderate – community-acquired & uncomplicated (hospitalized)

Drug	Dose	Route	Duration
Amoxicillin- clavulante	875 mg BID	РО	3 days, then reassess
Cefazolin	2 g IV q8h	IV	

Moderate - community-acquired & complicated (hospitalized)

Drug	Dose	Route	Duration
Ceftriaxone +	1 to 2 g q24h	IV	3 days, then reassess
Metronidazole	500 mg q12h	PO/IV	

Severe – health-care associated, late onset, septic shock, or ICU

Drug	Dose	Route	Duration
Piperacillin- tazobactam	3.375 g q6h	IV	3 days, then reassess

If penicillin/ceftriaxone allergy, use BOTH:

Drug	Dose	Route	Duration
Ciprofloxacin +	500 (400) mg q12h	PO (IV)	3 days, then reasses
Metronidazole	500 mg q12h	PO/IV	

Clostridioides difficile Infection

Diagnostic criteria for Clostridioides difficile infection include:

- Diarrhea (>3 unformed stools in 24 hours) AND
- [Positive toxigenic *C. difficile* or toxin **OR** colonoscopically or histopathologically-confirmed pseudomembranous colitis]

Non-severe (WBC <15 x 10⁹/L AND SCr <135 μmol/L) - Initial episode and first recurrence

Drug	Dose	Route	Duration
Vancomycin	125 mg QID	PO/NG	10 days
Metronidazole (if costs prohibits vancomycin use)	500 mg TID	PO/NG	10 days
Metronidazole (if unable to administer orally or enterally)	500 mg TID	IV	10 days

Non-severe (WBC <15 x 10⁹/L OR SCr <135 µmol/L)

- Second or more recurrence

Vancomycin	125 mg QID	PO/NG	10 days
Vancomycin PO/NG taper (e.g. 1)	25 mg BID x 7 c	lavs. then	125 mg

daily x 7 days and then 125 mg every 2 or 3 days x 2-8 weeks)

Severe (WBC >15 x 10⁹/L AND SCr >135 µmol/L)

Vancomycin	125 mg QID	PO/NG	10 days
Fulminant (hypotension, ileus, me	gacolon, shock)	
Vancomycin	125 mg QID	PO/NG	14 days
Vancomycin + Metronidazole (if complete ileus or critically ill)	125 mg QID 500 mg q8h	PO/NG IV	14 days
If vancomycin allergy/intolerance			
Fidaxomicin	200 mg BID	PO	10 days

Intra-abdominal Infection (IAI)

Community-Acquired IAI

Patient is admitted with an IAI present or develops IAI within 48 hours of hospitalization, where it is <u>not</u> the result of a previous contact with healthcare (e.g. invasive procedures or hospitalization).

Healthcare-Associated

Patient develops an IAI within 48 hours of admission with recent contact with healthcare (e.g. recent surgery or hospitalization) or after 48 hours of hospitalization



Intra-abdominal Infection Community-Acquired

Management should involve source control. Uncomplicated IAIs include non-perforated appendicitis or perforated appendix without established infection (i.e. OR within 24 hours of rupture). Oral stepdown should be considered as soon as patient tolerates oral intake.

Uncomplicated (involvement of source organ with source control)

Drug	Dose	Route	Duration	
Cefazolin + Metronidazole	2 g q 8h 500 mg q12h	IV PO/IV	24 hr post-op	
Complicated (extension beyond source organ with source control)				

Drug	Dose	Route	Duration
Ceftriaxone + Metropidazole	2 g q24h		3-5 days

Severe (septic shock or ICU)

Drug		Dose	Route	Duration
Piperacillin-tazobactam		3.375 g q6h	IV	Up to 7 days
If severe cefazolin/c	efti	riaxone/penicillin a	allergy	
Ciprofloxacin + Metronidazole	5(00 (400) mg q12h 500 mg q12h	PO (IV)	As above
Step-down option				
Amoxicillin- clavulanate	٤	375/125 mg BID	РО	As above
Community				







Intra-abdominal Infection Healthcare-Associated

Management should involve source control. Prolonged previous hospitalization (>5 days), anastomotic leak, perforation, and post-operative abscess. Oral step-down should be considered as soon as patient tolerates oral intake.

Mild-moderate (with source control), use BOTH:				
Drug	Dose	Rou	ite Duration	
Ceftriaxone +	2 g q24h	١v	/ 7 days	
Metronidazole	500 mg q12h	ו PO/	/IV	
Severe (septic shock or	ICU)			
Piperacillin-tazobactam	3.375 g q6h	١v	/ 7 days	
If ceftriaxone/penicillin	allergy, use BOTH:			
Ciprofloxacin +	500 (400) mg a	12h PO (IV) 7 days	
Metronidazole	500 mg BID	PO/	/IV 7 days	
→ If MRSA or <i>Enterococcus faecium</i> suspected, <u>ADD</u> :				
Vancomycin	Load 25 mg/k	g, IV	/ 7 days	
	then 15 mg/kg qa	3-12h		
\rightarrow If Candida spp suspected (in peritoneal fluid/tissue), <u>ADD</u> ONE of:				
Fluconazole	400 mg q24h	PO/IV	7 days	
Micafungin	100 mg q24h	IV	7 days	
Remember to check cultures, revise your				

diagnosis and consider oral Rx by day 3

Cystitis

Diagnosis of a urinary tract infection requires signs or symptoms to be present, including: dysuria, frequency, urgency, supra-pubic tenderness, and hematuria. Patients who have fever, flank pain, chills or CVA tenderness should be assessed for <u>pyelonephritis</u>. Cystitis spontaneously resolves in 50% of cases. Catheters should be removed or changed if present; this alone may resolve symptoms.

Uncomplicated, choose ONE of:

Drug	Dose	Route	Duration
Nitrofurantoin (MacroBID [®])	100 mg BID	РО	5 days
TMP-SMX	1 DS tab BID	PO	3 days
Cephalexin	250 to 500 mg QID	PO	5 days
Fosfomycin	3g (1 Sachet)	PO	Single dose

Complicated (male or urinary tract abnormality), choose ONE of:

Drug	Dose	Route	Duration
Nitrofurantoin (Macrobid®)	100 mg BID	РО	5-7 days
TMP-SMX	1 DS tab BID	РО	5-7 days
Amoxicillin- clavulanate	875 mg BID	РО	5-7 days
Cefuroxime	500 mg BID	РО	5-7 days
Cefixime	400 mg daily	РО	5-7 days



Pyelonephritis

Diagnosis of a urinary tract infection requires signs or symptoms to be present, including: dysuria, frequency, urgency, supra-pubic tenderness, and hematuria. Patients who have fever, flank pain, chills or CVA tenderness should be assessed for pyelonephritis.

Moderate (hospitalized)

Piperacillin-tazobactam

Drug	Dose	Route	Duration
Cefuroxime	500 mg BID	PO	7 days
Amoxicillin-clavulante	875 mg BID	PO	7 days
TMP-SMX	1 DS tab BID	PO	7 days
Cefixime	400 mg daily	РО	7 days

Moderate (hospitalized) and IV therapy required

Drug	Dose	Route	Duration
Ceftriaxone	1 g q24h	IV	7-10 days
Tobramycin	6 mg/kg q24h	IV	7-10 days

Second-line (if severe β-lactam/TMP-SMX/aminoglycoside allergy)

Drug	Dose	Route	Duration	
Ciprofloxacin	500 mg BID	PO	7 days	
Severe (septic shock or ICU, or known/suspected ESBL)				
Drug	Dose	Route	Duration	

OR if penicillin allergic:

Meropenem	500 mg q6h	IV	7-10 days
			A CONTRACT OF A

3.375 g q6h

IV



7-10 days

Cellulitis

Skin and soft tissue infections are most commonly caused by streptococci (non-purulent cellulitis) or staphylococci (purulent cellulitis). For soft tissue infections involving salt water contact, consider *Vibrio* coverage.

Non-purulent Cellulitis – mild (outpatient)

Drug	Dose	Route	Duration
Cephalexin	500 mg or 1000 mg QID	РО	5 days

Non-purulent Cellulitis - moderate (outpatient)

Cefazolin +	2 g q24h	IV	5-10 days
Probenecid	1 g daily (30 min before cefazolin)	РО	

→ If Purulent Cellulitis or Abscess AND MSSA suspected: Treat as above

→ If Purulent Cellulitis or Abscess AND MRSA suspected, ADD ONE of:

TMP-SMX	2 DS tablets BID	РО	5 days	
Doxycycline	100 mg BID	РО	5 days	
Second-line (if	cephalexin allergy)			
Clindamycin	600 mg TID	РО	5 days	
Severe (hospitalized) and IV therapy required				
Cefazolin	2 g q8h	IV	5-10 days	
Severe (hospitalized) and MRSA suspected:				
Vancomycin	15 mg/kg q12h	IV	5-10 days	
ENAD SNAX - trimothonrim culfamothoxazolo or co trimovazolo				

Diabetic Foot Infection Determine the Acuity

NON-INFECTED:

No signs of infection; no swelling, erythema, pain, warmth, or purulence; [NO signs of cellulitis; noninfected ulcer may have some surrounding erythema]

ACUTE MILD:

Local infection with 2 of: swelling, erythema, pain, warmth, or purulence; Cellulitis >0.5 cm to ≤2 cm around ulcer; [NO deep tissue or systemic toxicity]

ACUTE MODERATE:

Local infection with with cellulitis >2 cm or deep tissue involvement (e.g., abscess, osteomyelitis, septic arthritis, fasciitis); [NO systemic toxicity]

ACUTE SEVERE:

Local infection as described in "acute moderate" with systemic illness (e.g. fever, tachycardia, tachypnea, leukocytosis)



Diabetic Ulcer

New or chronic diabetic ulcers with no signs of infection should <u>not</u> be treated with antibiotics, however appropriate management is critical for preserving limb function. The following measures will help in wound healing and avoid adverse outcomes, such as amputation.

Reduce Pressure

Diabetic ulcers form as a result of pressure points that are not felt by the patient.

- Promote footwear that is comfortable, supportive, and protective.
- Ensure the patient or their care team inspects the feet regularly to recognize any new pressure-associated areas.

Improve Circulation

- Evaluate extremities for reduced circulation for all patients with diabetic ulcers.
- Consult vascular surgery for assessment.

Optimize Glycemic control

Involve GP or endocrinologist to target HgA1c of 8% or less

Promote Wound Healing

Consult wound-care team to optimize dressings and community wound care.





Diabetic Foot Infection Acute Mild

Acute diabetic foot infections should be treated quickly, but chronic infections require discussion of management goals and culture prior to treatment. Underlying causes, such as poor glycemic control and vascular compromise, should be discussed. Usual pathogens are streptococci and *S. aureus*. Oral therapy is preferred and narrowing by 48 hours based on culture results (e.g. stop MRSA coverage if cultures are negative).

Oral therapy					
Drug	Dose	Route	Duration		
Cephalexin	500 mg to 1000 mg QID	PO	7 days		
If IV therapy I	equired (change to PO wh	en possible	:)		
Cefazolin	2 g q8h	IV	7 days		
→ If purulent <u>AND MRSA suspected</u> , <u>ADD</u> ONE of:					
TMP-SMX	2 DS tabs BID	PO	7 days		
Doxycycline	100 mg BID	PO	7 days		
Second-line (if cephalexin allergy)					
Clindamycin	600 mg TID	РО	7 days		
Amoxicillin- clavulanate	875/125 mg BID	РО	7 days		
Image: Constraint of the second se					

Diabetic Foot Infection Acute Moderate

Acute diabetic foot infections should be treated quickly, but chronic infections require discussion of management goals and culture prior to treatment. Underlying causes, such as poor glycemic control and vascular compromise, should be discussed. Usual pathogens are polymicrobial. Severity should determine PO vs. IV therapy with narrowing based on culture results, investigations, and clinical improvement.

Oral Therapy (no evidence of osteomyelitis)			
Drug	Dose	Route	Duration
Amoxicillin- clavulanate	875 mg BID	РО	7-14 days

If IV therapy required or osteomyelitis suspected, use BOTH:

Ceftriaxone +	2 g IV q24h	IV	ID consult
Metronidazole	500 mg q12h	PO/IV	recommended

\rightarrow If purulent <u>AND</u> MRSA suspected, <u>ADD</u> ONE of:

TMP-SMX	2 DS tabs BID	РО	7-14 days
Doxycycline	100 mg BID	РО	7-14 days

Second-line (if penicillin/amoxicillin allergy), use BOTH:

Clindamycin +	300 mg to 600 mg TID	РО	7-14 days
Ciprofloxacin	500 to 750 mg BID	PO	







Diabetic Foot Infection Acute Severe

Depth and chronicity of ulcer are not measures of severity, but rather the rapidity of progression. Therapy should be used to prevent potential limb loss or progression to systemic disease (e.g. sepsis). Start with 7 days and adjust regimen as required; duration will be affected by presence of osteomyelitis. Deep tissue cultures should be taken and antibiotic choice tailored to culture results. ID consult is recommended.

First-line (no known or suspected resistance), use BOTH:

Drug	Dose	Route	
Ceftriaxone +	2 g IV q24h	IV	7-14 days
Metronidazole	500 mg q12h	PO/IV	

If septic shock or suspected ceftriaxone-resistance					
Piperacillin-	3.375 g q6h	IV	7-14 days		

If penicillin/ceft	riaxone allergy or	r known	resistance	

-			
Meropenem	500 mg q6h	IV	7-14 days

\rightarrow If MRSA suspected, <u>ADD</u>:

Vancomycin	Load 25 mg/kg,	IV	7-14 days
	then 15 mg/kg q8-12h		



tazobactam





Febrile Neutropenia

Febrile neutropenia is defined as:

- Temperature >38.3°C AND
- Absolute neutrophil count <500/mm³ or expected to decrease to <500/mm³ within 48 hours

High Risk – inpatient (empiric therapy)

Drug	Dose	Route	Duration		
Piperacillin- tazobactam	4.5 g q6h	IV	-		
If penicillin/ceftriaxone allergy or known resistance					

Ceftazidime <u>+</u>	2 g q8h	IV	-
Metronidazole	500 mg q12h	PO/IV	
(if intraabdominal			
source suspected)			

If severe penicillin/ceftriaxone anaphylaxis OR if ESBL suspected or documented

Meropenem	500 mg q6h	IV	-
-----------	------------	----	---

→ If hemodynamically unstable/septic; pneumonia; blood culture positive for Grampositive bacteria; serious catheter-related infection; serious skin or soft tissue infection; MRSA known/suspected; severe mucositis on fluoroquinolone prophylaxis, <u>ADD</u>:

Vancomycin	Load 20 mg/kg, then 15 mg/kg q8-12h		IV	-	
Low Risk – outpatient (empiric therapy)					
Amoxicillin-clavu Ciprofloxad	lanate + :in	875 mg BID 750 mg BID	PO PO	-	
Clindamycir Ciprofloxad	n + :in	600 mg TID 750 mg BID	РО		

Sepsis

Empiric broad-spectrum intravenous antibiotic therapy should be started within the first hour of severe sepsis and septic shock, preferably after blood cultures have been collected. Source control within 12 hours of the <u>diagnosis</u> is critical. Recommended duration of therapy is usually 7 days; 14 days minimum for *S. aureus* pneumonia/bacteremia and longer courses may be required in persistent bacteremia (rule out endocarditis), fungemia, inadequate source control, slow clinical response, or neutropenia. Consider consulting ID.

Unknown source

Piperacillin-	3.375 g q6h	IV	7 days
tazobactam			

If severe penicillin allergy, known resistance, or septic shock

Meropenem	500 mg q6h	IV	7 days

→ If MRSA suspected or septic shock, <u>ADD</u>:

Vancomycin	Load 30 mg/kg, then	IV	7-14 days
	20 mg/kg q8-12h		









Antimicrobial Stewardship Programme: Innovation, Research, Education, and Safety

Assess Patients Daily to Optimize Antibiotics

Bioequivalent IV to PO agents:

Ciprofloxacin Clindamycin Co-trimoxazole Fluconazole Linezolid Metronidazole Moxifloxacin Voriconazole

<u>Checklist for IV to PO Step-</u> <u>down:</u> Continues to need antiinfective; Clinically stable; Tolerates PO; No factors affecting PO absorption

Minimum Duration of Therapy: Cellulitis: 5d Cystitis: 3d SBP: 5d Pneumonia: 5d Pyelonephritis: 7d VAP: 7d <u>Criteria for Discontinuing</u> <u>Anti-infectives:</u> Completed minimum duration of therapy; Source is controlled; Clinically improved to baseline; Alternative diagnosis

Questions? Talk to ASPIRES or your Clinical Pharmacist